Regulation of the expression of 5-lipoxygenase-activating protein/5-lipoxygenase and the synthesis of leukotriene B4 in osteoarthritic chondrocytes: Role of transforming growth factor β and eicosanoids

Arthritis and Rheumatism

Volumn 50, Issue 12, 2004, Pages 3925-3933

  Martel Pelletier, Johanne ^a   Mineau, François ^a   Fahmi, Hassan ^a   Laufer, Stefan ^b   Reboul, Pascal ^a   Boileau, Christelle ^a   Lavigne, Martin ^c   Pelletier, Jean Pierre ^a  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CALCITRIOL; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ICOSANOID; INTERSTITIAL COLLAGENASE; LEUKOTRIENE B4; LICOFELONE; LIPOXYGENASE; LIPOXYGENASE 5; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARTILAGE CELL; CATABOLISM; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; MODULATION; OSTEOARTHRITIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNTHESIS; UPREGULATION;

ARACHIDONATE 5-LIPOXYGENASE; CALCITRIOL; CARRIER PROTEINS; CARTILAGE, ARTICULAR; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; LEUKOTRIENE B4; MATRIX METALLOPROTEINASE 1; MEMBRANE PROTEINS; MIDDLE AGED; NITRIC OXIDE; OSTEOARTHRITIS, KNEE; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 10444285029     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20632     Document Type: Article

References (42)

1. Pelletier JP, Martel-Pelletier J, Howell DS. Etiopathogenesis of osteoarthritis. In: Koopman WJ, editor. Arthritis and allied conditions: a textbook of rheumatology. 14th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2195-245.
2. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 2003;62:501-9.
3. Kuehl FA Jr, Dougherty HW, Ham EA. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984;33:1-5.
4. 4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 1993;34:742-7.
5. 4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 2002;46:1804-12.
6. Celotti F, Durand T. The metabolic effects of inhibitors of 5-lipoxygenase and of cyclooxygenase 1 and 2 are an advancement in the efficacy and safety of anti-inflammatory therapy. Prostaglandins Other Lipid Mediat 2003;71:147-62.
7. Reboul P, Marcouiller P, Laufer S, Martel-Pelletier J, Pelletier JP. Study of cross talking between leukotriene and prostaglandin synthetic pathways in human osteoarthritic synovial membranes: mechanisms of regulation [abstract]. Ann Rheum Dis 2003;62:H1001.
8. Henderson WR Jr. The role of leukotrienes in inflammation. Ann Intern Med 1994;121:684-97.
9. Peters-Golden M, Brock TG. 5-lipoxygenase and FLAP. Prostaglandins Leukot Essent Fatty Acids 2003;69:99-109.
10. Matsumoto T, Funk CD, Radmark O, Hoog JO, Jornvall H, Samuelsson B. Molecular cloning and amino acid sequence of human 5-lipoxygenase. Proc Natl Acad Sci U S A 1988;85:26-30.
11. Dixon RA, Jones RE, Diehl RE, Bennett CD, Kargman S, Rouzer CA. Cloning of the cDNA for human 5-lipoxygenase. Proc Natl Acad Sci U S A 1988;85:416-20.
12. Rouzer CA, Kargman S. Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. J Biol Chem 1988;263:10980-8.
13. Miller DK, Gillard JW, Vickers PJ, Sadowski S, Leveille C, Mancini JA, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990;343:278-81.
14. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990;343:282-4.
15. 2-like activity in synovial fluid in osteoarthritis. Prostaglandins Leukot Essent Fatty Acids 1990;39:253-4.
16. Wittenberg RH, Willburger RE, Kleemeyer KS, Peskar BA. In vitro release of prostaglandins and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases. Arthritis Rheum 1993;36:1444-50.
17. 4-induced interleukin-1β in synovial cells from patients with rheumatoid arthritis. Scand J Rheumatol 1994;23:148-50.
18. Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture: comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol 1996;48:46-52.
19. Jovanovic DV, Fernandes JC, Martel-Pelletier J, Jolicoeur FC, Reboul P, Laufer S, et al. The in vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis: suppression of collagenase 1 and interleukin-1β synthesis. Arthritis Rheum 2001;44:2320-30.
20. He W, Pelletier JP, Martel-Pelletier J, Laufer S, Di Battista JA. The synthesis of interleukin-1β, tumour necrosis factor-α and interstitial collagenase (MMP-1) is eicosanoid dependent in human OA synovial membrane explants: interactions with anti-inflammatory cytokines. J Rheumatol 2002;29:546-53.
21. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. Development of criteria for the classification and reporting of osteoarthritis: classification of osteoarthritis of the knee. Arthritis Rheum 1986;29:1039-49.
22. Mankin HJ, Dorfman H, Lippiello L, Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg Am 1971;53:523-37.
23. Pelletier JP, Martel-Pelletier J, Howell DS, Ghandur-Mnaymneh L, Enis JE, Woessner JF Jr. Collagenase and collagenolytic activity in human osteoarthritic cartilage. Arthritis Rheum 1983;26:63-8.
24. Martel-Pelletier J, Pelletier JP, Cloutier JM, Howell DS, Ghandur-Mnaymneh L, Woessner JF Jr. Neutral proteases capable of proteoglycan digesting activity in osteoarthritic and normal human articular cartilage. Arthritis Rheum 1984;27:305-12.
25. Reboul P, Pelletier JP, Tardif G, Cloutier JM, Martel-Pelletier J. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes: a role in osteoarthritis. J Clin Invest 1996;97:2011-9.
26. Fernandes JC, Martel-Pelletier J, Jovanovic D, Tardif G, Di Battista JA, Lascau-Coman V, et al. Effects of tenidap on canine experimental osteoarthritis. II. Study of the expression of collagenase-1 and IL-1β by in situ hybridization. J Rheumatol 1998;25:951-8.
27. 15N]nitrate in biological fluids. Anal Biochem 1982;126:131-8.
28. 3 upregulates 5-lipoxygenase metabolism and 5-lipoxygenase activating protein in peripheral blood monocytes as they differentiate into mature macrophages. J Lipid Mediat 1993;6:43-51.
29. Steinhilber D, Radmark O, Samuelsson B. Transforming growth factor β upregulates 5-lipoxygenase activity during myeloid cell maturation. Proc Natl Acad Sci U S A 1993;90:5984-8.
30. 3. Proc Natl Acad Sci U S A 1995;92:107-11.
31. Moldovan F, Pelletier JP, Mineau F, Dupuis M, Cloutier JM, Martel-Pelletier J. Modulation of collagenase 3 in human osteoarthritic cartilage by activation of extracellular transforming growth factor β: role of furin convertase. Arthritis Rheum 2000;43:2100-9.
32. Tetlow LC, Woolley DE. Expression of vitamin D receptors and matrix metalloproteinases in osteoarthritic cartilage and human articular chondrocytes in vitro. Osteoarthritis Cartilage 2001;9:423-31.
33. Lajeunesse D, Martel-Pelletier J, Fernandes JC, Laufer S, Pelletier JP. Treatment with licofelone prevents abnormal subchondral bone cell metabolism in experimental dog osteoarthritis. Ann Rheum Dis 2004;63:78-83.
34. Laufer S, Tries S, Augustin J, Elsasser R, Albrecht W, Guserle R, et al. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4- chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. Arzneimittelforschung 1995;45:27-32.
35. Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem - the dual inhibition concept. Pharmacol Res 2001;43:429-36.
36. 4 synthase activities in human chondrocytes: transcellular biosynthesis of leukotrienes during granulocyte-chondrocyte interaction. Arthritis Rheum 1998;41:1645-51.
37. Chen XS, Sheller JR, Johnson EN, Funk CD. Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 1994;372:179-82.
38. Goulet JL, Snouwaert JN, Latour AM, Coffman TM, Koller BH. Altered inflammatory responses in leukotriene-deficient mice. Proc Natl Acad Sci U S A 1994;91:12852-6.
39. Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Strieter R, Peters-Golden M. Leukotriene-deficient mice manifest enhanced lethality from Klebsiella pneumonia in association with decreased alveolar macrophage phagocytic and bactericidal activities. J Immunol 1996;157:5221-4.
40. Irvin CG, Tu YP, Sheller JR, Funk CD. 5-Lipoxygenase products are necessary for ovalbumin-induced airway responsiveness in mice. Am J Physiol 1997;272:L1053-8.
41. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001;2:612-9.
42. Fermor B, Haribabu B, Weinberg JB, Pisetsky DS, Guilak F. Mechanical stress and nitric oxide influence leukotriene production in cartilage. Biochem Biophys Res Commun 2001;285:806-10.